Senior insider sale
Chief Medical Officer at AVALO THERAPEUTICS, INC. — senior position signals high conviction
$1.41M
86.33K shares
What this filing means
DOYLE MITTIE plans to sell 86.33K shares of AVALO THERAPEUTICS, INC. valued at approximately $1.41M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 5/6/2026ACC: 0001950047-26-004154
Officer· Chief Medical Officer
Since Feb 2026
86.33K
Shares to sell
$1.41M
Approx. market value
54.51K
Acquired (3 months)
1
Planned
4 completed
Securities Acquired — Last 3 Months1
Exercise of Stock Options
Cash
5/6/2026
54.51KTotal acquired54.51K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
5/6/2026 | Exercise of Stock Options Cash | 54.51K | — |
| Total | 54.51K | ||
Planned & Completed Dispositions5
Completed
—Completed
Units to sell
1.68K
Market value
$26.9K
5/5/2026
—Completed
Units to sell
3.97K
Market value
$71.5K
4/6/2026
—Completed
Units to sell
679.00
Market value
$10.9K
4/1/2026
—Completed
Units to sell
25.49K
Market value
$411.6K
3/16/2026
Planned — Approximate Date
NASDAQPlanned
Units to sell
54.51K
Market value
$886.3K
5/6/2026
Total
Units
86.33K
Value
$1.41M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
5/5/2026 | 1.68K | $26.9K | — | Completed |
4/6/2026 | 3.97K | $71.5K | — | Completed |
4/1/2026 | 679.00 | $10.9K | — | Completed |
3/16/2026 | 25.49K | $411.6K | — | Completed |
| Planned — Approximate Date | ||||
5/6/2026 | 54.51K | $886.3K | NASDAQ | Planned |
| Total | 86.33K | $1.41M | ||